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Abstract
Background: There is no standard treatment pathway for tinnitus patients in the UK. Possible therapies include
education and reassurance, cognitive behavioural therapies, modified tinnitus retraining therapy (education and
sound enrichment), or amplification of external sound using hearing aids. However, the effectiveness of most
therapies is somewhat controversial. As health services come under economic pressure to deploy resources more
effectively there is an increasing need to demonstrate the value of tinnitus therapies, and how value may be
continuously enhanced. The objective of this project was to map out existing clinical practice, estimate the
NHS costs associated with the management approaches used, and obtain initial indicative estimates of cost-
effectiveness.
Methods: Current treatment pathways, costs and health outcomes were determined from the tinnitus literature,
national statistics, a patient survey, and expert opinion. These were used to create an Excel-based economic model
of therapy options for tinnitus patients. The probabilities associated with the likelihood of an individual patient
receiving a particular combination of therapies was used to calculate the average cost of treatment per patient,
average health outcome per patient measured in QALYs gained, and cost-effectiveness, measured by the average
cost per QALY gained.
Results: The average cost of tinnitus treatment per patient per year is GB£717, equating to an NHS healthcare bill of
GB£750 million per year. Across all pathways, tinnitus therapy costs £10,600 per QALY gained. Results were relatively
insensitive to restrictions on access to cognitive behaviour therapy, and a subsequent reliance on other therapies.
Conclusions: NHS provisions for tinnitus are cost-effective against the National Institute for Health and Care
Excellence cost-effective threshold. Most interventions help, but education alone offers very small QALY gains.
The most cost-effective therapies in the model were delivered within audiology.
Keywords: Tinnitus, Hearing aids, Cost effectiveness, Ear nose and throat, General practice, Audiology, Clinical
psychology, Cognitive behaviour therapy, Hearing aids
Background
Tinnitus is the phantom sensation of sound, often a
ringing, hissing, or buzzing that is experienced by about
10% of the population. It is often medically unexplained
(subjective), chronic, and for some people can significantly
impair quality of life [1–3]. Clinical management for the
most part relies on counselling or cognitive therapy [4, 5],
managing any associated hearing difficulties with hearing
aid amplification [6], or masking the tinnitus percept using
sound devices such as hearing aids or sound generators
[7, 8]. Most tinnitus management options are poorly
researched and might be considered experimental or even
controversial [9, 10].
The most commonly offered treatment modality is a
combination of education, counselling, and sound ther-
apy based on a neurophysiological model of tinnitus
[11]. The clinical correlate of this model has been pub-
lished as a formal management paradigm called Tinnitus
Retraining Therapy (TRT) [12]. TRT per protocol is re-
source intensive and is not generally funded within the
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UK National Health Service (NHS). A pared down ver-
sion of TRT is, however, widely used and is referred to
as modified TRT (MTRT; [13]) in the current study.
Although a best practice commissioning guide for pri-
mary, secondary, and tertiary services for tinnitus has been
published by the Department of Health [14], services
across the UK vary enormously in terms of the patient
pathway and the treatments that are offered or available.
Audiology services for tinnitus may be accessible either
directly via the GP, or only indirectly via GP referral to
ENT [15]. By either route, referral rates differ dramatically
across GPs [16]. Only two thirds of services offer some
form of cognitive behavioural therapy (CBT), and clinical
psychologists are rarely accessible [17].
In the developed world, tinnitus can be associated with
significant healthcare costs. A retrospective US study by
Goldstein et al. [18] estimated the healthcare cost of tin-
nitus to be around US$660 per patient per year, while in
the Netherlands Maes et al. [19] have estimated the
mean annual tinnitus-related healthcare cost per patient
to be €1544.
In the UK, the incidence of bothersome tinnitus pre-
senting to the NHS is increasing [20], giving rise to in-
creasing costs. There is a need to examine the costs of
tinnitus care in the UK, and provide a benchmark for
the economic evaluation of new therapies or pathway
redesign studies.
Methods
Study design
The study involved a collaborative effort between the
British Tinnitus Association (DS), Optimity Advisors
(PB, CP), and an advisory group comprising members with
expertise in tinnitus, from backgrounds in audiology (TK,
Beth-Anne Culhane, Peter Byrom), ENT (DM), General
Practice (CD), and research (DJH). It is reported according
to the consolidated health economic evaluation reporting
standards (CHEERS; [21]).
We mapped out the clinical pathways and treatment
options used in people presenting to their GP with
symptoms of tinnitus. Costs and probabilities of a patient
receiving a particular treatment were attached to the vari-
ous treatments along the different clinical pathways in
order to generate an overall average NHS treatment cost.
Clinical pathways were defined based on expert clinical
opinion. The intention was to produce a framework which
broadly describes existing treatment patterns in the NHS
for tinnitus patients. The model developed therefore does
not compare different treatment options for a population
with given characteristics who have tinnitus. Rather, it pro-
vides a baseline for the overall treatment costs and health
outcomes for the generality of patients with tinnitus, given
a set of assumptions about the likelihood of being man-
aged in various ways.
An Excel model was constructed mapping out the most
common treatment pathways (involving education and re-
assurance, discharge and self-management, hearing aids,
CBT, MTRT, clinical psychology) and a cohort of patients
run through the model. The range of treatment options in
the model is not exhaustive of all possibilities as there may
be atypical local models, or patients may leave a tinnitus
pathway to enter a mainstream mental health pathway or
a non-NHS healthcare service. Variation in the severity of
tinnitus was not explicitly incorporated into the model.
The only feature distinguishing patients in terms of clin-
ical presentation was candidacy for hearing aids which is
determined only after referral from the GP for further as-
sessment; note practices in the prescription of hearing aids
for tinnitus management are highly variable, particularly
where there is milder or higher frequency hearing loss,
and are very much influenced by the clinical experience
and opinion of individual audiologists [6]. Drawing on
previous modelling work, tinnitus patients either did or
did not experience an improvement in their condition.
Those who experienced an improvement either success-
fully habituated (were ‘cured’) or did not successfully
habituate. Those who did not successfully habituate were
discharged to self-management. Those whose tinnitus
does not improve can be referred on for further treatment.
Of the cohort of patients presenting to a GP for the
first time, an estimated 30% are referred to ENT, 7% are
referred to audiology and 63% receive education and re-
assurance from the GP and are not referred onwards
[16]. Patients who are unsuccessful in habituating to their
condition after seeing their GP are subsequently referred
to ENT or audiology. Figures 1 and 2 present illustrative
pathways captured by the model. Those undergoing evalu-
ation by an audiologist or Ear Nose and Throat (ENT)
specialist can be referred on for further treatment with
modified tinnitus retraining therapy (MTRT) or cognitive
behavioural therapy (CBT). For simplicity, Fig. 2 illustrates
the treatment options for those not considered candidates
for hearing aids. For those considered candidates for hear-
ing aids on audiological/ENT assessment, the treatment
options corresponding to MTRT and CBT are education
and reassurance, hearing aids and maintenance, CBT plus
hearing aids and maintenance and MTRT plus hearing
aids and maintenance. We acknowledge that it may not be
appropriate to allocate the entire cost of hearing aids to
the treatment of tinnitus. However, given the difficulty of
estimating the proportion attributable and in order not to
bias the analysis in favour of treatment for tinnitus, we
included the full cost of hearing aids, and conducted a
sensitivity analysis to test the effect of this assumption.
It is assumed that the time from initial GP consult-
ation to eventual successful habituation or discharge will
be less than 12 months. Hence new treatment interventions
will have all been exploited in the first year. Recurring costs
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are those associated with ongoing support. For example,
the costs of hearing aid maintenance will be incurred over
the lifetime of the patient. Annual costs were discounted at
a rate of 3.5% per annum as used by NICE for health
technology appraisals. The result is the present value of
the lifetime cost for a patient following each of the defined
clinical pathway options.
Sources of probabilities
The analysis draws on a number of sources of probabilities
(Additional file 1). These include key journal publications,
the results of a yet unpublished survey of the experiences
of members of British Tinnitus Association (BTA), na-
tional statistics, and the clinical expert knowledge of
the study team. Expert opinion was used to formulate a
consensus, through discussion, on the current common
clinical pathways followed by tinnitus patients.
Research evidence was used to estimate the following
parameter values: the probability that tinnitus improves
after CBT [22], the probability of receiving a hearing aid
prescription [23], the probability that tinnitus improves
after MTRT/CCBT and hearing aids [24], the probability
of receiving a hearing aid [25], the probability of onward
referral by GP and reattendance [16], the probability of
improvement after hearing aid fitting or education and
reassurance [26], the probability of receiving an audiology
intervention, [15, 27, 28], CBT effectiveness [29], the
probability of receiving MTRT [30], and the probability
that tinnitus improves after CBT and hearing aids [31].
Member survey data were used to estimate values for an-
other group of variables in the model such as the propor-
tion of patients discharged rather than having onward
referral by ENT. Remaining transition probabilities were
obtained from a survey of experts, with disagreement (and
logical inconsistencies) resolved by consensus.
Comparator
The implicit comparator was a patient who did not seek
treatment for their condition and was assumed to incur
zero tinnitus-related NHS treatment costs. In addition
to treatment costs, a quality adjusted life year (QALY)
gain was attributed to those patients who successfully
habituated compared with those who are discharged at
any stage and left to self-manage and relative to those
who do not seek treatment. In the absence of good nat-
ural history data at the time of analysis, a hypothetical
zero cost, zero QALY cohort at least provides a common
comparator.
Modelling common tinnitus pathways
Probabilities
Table 1 gives illustrative examples of numbers following
given pathways and the numbers of those habituating to
Fig. 1 Clinical pathways. Initial presentation in the model starts with a General Practitioner (GP) consultation progressing to successive levels of
onward referral, treatment, and ending with successful habituation (health benefit) or discharge to self-manage (no health benefit). ENT = ear nose
and throat surgeon. Follow on treatment pathways are given in Fig. 2. Pathways are identified by letter (red text) and correspond to those in Table 1
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their condition. Further description of these pathways is
given in Additional file 2.
Costs
The direct NHS healthcare costs were captured or esti-
mated for each clinical pathway including the costs of
clinical consultations (GP, ENT, audiologist/hearing
therapist, clinical psychologist), diagnostic assessments,
and management options including sound devices (hear-
ing aids, sound generators), pharmacotherapy, CBT, and
MTRT. Unit costs and source references used in the
model are given in Table 2 and Additional file 3. A
Fig. 2 Follow-on treatment pathways. Following on from ENT/Audiology examination and review tinnitus patients progress to successive levels
of onward referral, treatment, and ending with successful habituation (health benefit) or discharge to self-manage (no health benefit). CBT = cognitive
behaviour therapy; ENT = ear nose and throat surgeon; MTRT = modified tinnitus retraining therapy. For those considered candidates for hearing aids
the treatment options corresponding to MTRT and CBT are education and reassurance, hearing aids and maintenance, CBT plus hearing aids and
maintenance, and MTRT plus hearing aids and maintenance
Table 1 Probabilities of overall distribution of 100 tinnitus patients to pre-defined patient pathways, successful habituation, and
discharge to self-management
Route Total
people
Total number of successful
habituation
Total number of people
discharged to self-manage
A GP to Education and reassurance 23.31 13.29 10.02
B GP to Education and reassurance to Audiology 14.40 4.28 10.11
C GP to Education and reassurance to Audiology to ENT/audiovestibular
medicine
1.08 0.01 1.07
D GP to Education and reassurance to ENT/audiovestibular medicine 16.95 0.17 16.78
E GP to Education and reassurance to ENT to Referral to audiology 7.26 2.16 5.10
F GP to ENT/audiovestibular medicine 21.00 0.21 20.79
G GP to ENT/audiovestibular medicine to Follow-on audiology 9.00 2.68 6.32
H GP to Audiology 6.51 1.936 4.574
I GP to Audiology to ENT/audiovestibular medicine 0.4900 0.0053 0.4847
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number of assumptions related to how often costs are
incurred were derived from expert knowledge and the
BTA member survey. Examples of modelling assump-
tions are that:
 50% of patients seen in audiology/ENT/
audiovestibular medicine undergo an MRI scan;
 hearing aids are reassessed and replaced every 4 years;
 follow-up, repairs and maintenance of hearing aids
are undertaken annually;
 replacement of packs of 6 hearing aid batteries
occurs 6 times a year;
 one pair of hearing aids is issued to all patients using
this management modality;
 patients receive on average two GP appointments
before they are first referred onwards;
 patients treated by a Clinical Psychologist are seen
twice in the initial year.
The total annual healthcare cost of tinnitus in the
NHS was calculated by multiplying the average cost per
pathway by the proportion of patients per pathway in
the model, and the estimated annual number of patients
seeking NHS care for tinnitus in the UK.
Health outcomes
Health outcomes from a patient perspective were expressed
in terms of quality adjusted life years (QALYs) per person
where QALYs gained represent the number of years in
good health which can be expected over the individual’s
remaining lifetime (assumed to be 35 years) under NHS
treatment relative to the comparator of no NHS treatment.
Patients who successfully habituate to tinnitus gain QALYs,
whereas patients who are discharged without treatment
and self-manage in an undirected way have no QALY gain.
An annual QALY gain of +0.02 (discounted QALY over
35 years = 0.4) was applied for all patients who successfully
habituated to their tinnitus. No directly relevant studies on
quality of life improvement suitable for calculating QALYs
were found. However, an average ear disease pre-post man-
agement score on the Health Utilities Index mark 3 (Hui-3
[32]) has been reported by Swan et al. [33]. It was assumed
that the pre-treatment quality of life applies over the life-
time for those who do not seek NHS care. The annual
QALY gains in future years were discounted at a rate of
3.5% to determine a present value of lifetime health benefit.
Cost-effectiveness
Cost-effectiveness results were obtained by multiplying
the relevant costs, QALYs and probabilities along each
pathway considered. The assumptions underlying the
cost-effectiveness results need to be borne in mind when
interpreting the results presented below. As the main
purpose of the study was to cost the range of possible
pathways for the management of tinnitus, the cost-
effectiveness results should be regarded as illustrative.
We acknowledge the limitations of the analysis and
highlight areas for further research in a later section.
Results
Cost effectiveness of treating tinnitus
Costs and health outcomes are not reported here for all
the pathways identified in Figs. 1 and 2. Costs, QALYs,
and cost per QALY gained (relative to no treatment) are
reported for those who habituate to their condition after
receiving education and reassurance only, and for those
whose condition does not improve and who are referred
to, or who are referred directly by their GP, to:
 Audiology
 Ear Nose and Throat (ENT)/audiovestibulary
medicine review
 Audiology followed by ENT review
 ENT review followed by audiology
This gives eight additional pathways: those referred
directly to one of these four and those whose condition
does not improve following education and reassurance
by the GP. The results for each pathway summarise the
Table 2 Annual tinnitus-related treatment costs
Treatment Yearly cost
Digital Hearing Aids £85.00a
Hearing aids assessments £65.00a
Hearing aids fitting £65.00a
Hearing aids follow up £108.00a
Hearing aid batteries £12.00b
Hearing Aid Repairs £52.00a
Cognitive Based Therapy (CBT) (all associated staff,
diagnostic and operating cost and consist of
3 sessions per year)
£471.00a
Tinnitus Therapy plus wearable sound generator
(3 sessions with mid-point band level 6 for an
allied health care professional)
£303.00c
GP session (11.7 min) £52.00c
Pharmacotherapy - betahistine £25.12d
Pharmacotherapy - Amitriptyline £13.29e
Magnetic Resonance Imaging (MRI) £85.00a
Associate Medical Specialist in ENT/Audiovestibular
medicine (1 h)
£121.00c
Audiologist (1 h) £18.76e
Clinical Psychologist (2 h) £268.00c
aNHS trust reference cost schedules 2012–2013
[41] https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-
2013
bwww.hearing-aid-batteries.org.uk [42]
cUnit costs of Health and Social Care
2013.http://www.pssru.ac.uk/project-pages/unit-costs/2013/ [43]
dNational Drug tariff https://www.nhsbsa.nhs.uk/nhs-prescription-services [44]
eexpert opinion
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costs and QALYs accrued by patients over the course of
their remaining treatments, potentially up to consult-
ation with a clinical psychologist. The results are there-
fore averages for those who successfully habituate and
those who do not successfully habituate at the end of
their treatment journey. These ‘root’ pathways include
those considered candidates for hearing aids (following
ENT or audiology examination) as well as those who
were not considered candidates.
Table 3 shows the costs and QALY gains for these
pathways. Results for the first treatment possibility, edu-
cation and reassurance from the GP, are reported for
those whose tinnitus improves and who habituate to
their condition or are discharged to self-management.
The other pathways relate to those whose condition does
not improve after GP education and reassurance and are
referred to audiology/ENT or are referred directly to
audiology/ENT. Across all pathways, tinnitus therapy
costs GB£10,600 per QALY gained and would be regarded
as cost-effective against the NICE benchmark of GB
£20,000 per QALY gained.
In the model the proportion of patients discharged dir-
ectly from ENT is significantly higher than the propor-
tion discharged from audiology. Of the small number of
patients who are referred to ENT after seeing an audi-
ologist, 97% of patients are discharged and self-manage
after a full diagnostic review. In practice, patients who
are referred to audiology are more likely to receive an
intervention such as CBT, MTRT, with only 10% estimated
to be discharged to self-management. Thus, the model
generates a much higher cost per QALY for those pathways
in which access to MTRT/CBT is mediated by ENT. Cau-
tion should be used when interpreting the results as they
do not represent competing options for patients with given
characteristics but are intended to capture the way in
which patients (of all types) are managed in practice.
Therefore, there may be clinical grounds for some patients
being eligible for certain pathways and not others. The ex-
treme cost-effectiveness ratio is due to the impact created
from the number of patients who are discharged from
the model at an early stage, receiving no treatment and
therefore in our model having no improvement in health
outcome.
Sensitivity analyses
The sensitivity of the results to changes in the assump-
tions underlying the particularly high cost-effectiveness
ratios associated with the ENT pathways was explored.
In an early iteration of the model, the proportion of pa-
tients discharged rather than having onward referral by
ENT following GP education and reassurance was esti-
mated by the advisory panel to be just 15%. This would
have given a cost effectiveness ratio of £7043/QALY for
the GP to educational reassurance to ENT pathway. In
comparison, the final model was revised using data from
the members’ survey which placed the estimated discharge
rate at 68% of those referred directly to ENT, and 97% of
those referred from audiology to ENT. This is an import-
ant disparity between member report and clinician opin-
ion that warrants further investigation.
A simulation was run to explore the effect of only allo-
cating a proportion of the cost of hearing aids to tinnitus
benefit. Hearing aids are often prescribed in the pres-
ence of tinnitus, but always with associated hearing loss,
so some of the cost might reasonably be associated with
improvements in listening abilities. In a sensitivity analysis
where only 50% of the cost of hearing aids was attributed
to the treatment of tinnitus the overall cost-effectiveness
ratio was slightly reduced, to £9901/QALY.
A further simulation was run to examine the effect
that varying the estimate of successful habituation would
have on cost effectiveness ratios. In a simulation where
only 20% of patients successfully habituate and 80% are
discharged to self-manage after GP education and re-
assurance, the overall cost-effectiveness ratio increases
to around £13,000/QALY. If only 15% of patients success-
fully habituated then the cost-effectiveness ratio would
be around GB£18,600; if any fewer patients than 18% of
Table 3 Costs and outcomes for key tinnitus management pathways
Pathway Average Cost per person Average QALY gain per person Cost per QALY
GP to education and reassurance - tinnitus improves £59 0.23 £258
GP to Educational reassurance to Audiologist £2378 0.12 £19,988
GP to Educational reassurance to Audiologist to ENT £354 0.004 £82,523
GP to Educational reassurance to ENT £335 0.004 £83,250
GP to Educational reassurance to ENT to Audiologist £2504 0.12 £21,015
GP to ENT £335 0.004 £83,250
GP to ENT to Audiology £2504 0.12 £21,015
GP to Audiology 2378 0.12 £19,988
GP to Audiology to ENT £354 0.004 £82,523
Average across all pathways £1051 0.10 £10,616
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patients at this point successfully improved then the
cost effectiveness ratio was greater than the NICE GB
£20,000 benchmark.
Further simulations were run to assess the effect of
varying the QALY gain estimate. An estimated gain of
0.04 reduced the cost effectiveness ratio to less than GB
£7000/QALY. If the gain was half that predicted, i.e.
0.01, then the cost effectiveness ratio would be around
£15,000/QALY.
Estimated total NHS healthcare cost of tinnitus
The average tinnitus-related healthcare cost per patient
per year in the model was GB£717. Based on there being
43,900 GPs in the UK (nuffieldtrust.org.uk), each seeing
two patients per month where the primary complaint is
tinnitus [16] we estimate that 1.05 million GP consulta-
tions for tinnitus are conducted each year. As an esti-
mate of total UK annual healthcare expenditure on
tinnitus, this figure was multiplied by the average annual
pathway cost per-patient (GB£717). This gives a UK
healthcare cost of tinnitus in the region of GB£750 mil-
lion which equates to about 0.6% of current annual pub-
lic sector spending on healthcare in the UK [34]. If the
relationship between healthcare and societal cost is pro-
portionate to that reported by Maes et al. [19] then the
societal cost of tinnitus to the UK is in the region of GB
£2.7 billion per annum; however, empirical evidence is
needed for a truer estimate.
Discussion
This cost study benefited from an approach which syn-
thesised different forms of evidence and expert know-
ledge to ensure the validity of the different approaches
to tinnitus care evaluated. Overall, with a cost per QALY
of GB£10,600, tinnitus therapy as currently delivered in
the NHS is cost effective against the NICE benchmark of
GB£20,000 per QALY gained. Cost effectiveness would
be maintained if only 15% of patients successfully habit-
uated to their tinnitus. The estimated cost-effectiveness
is in line with those of Cima et al. [23] who trialled a
specialised multi-disciplinary care package for tinnitus,
estimating it to cost US$10,456–$24,580 per QALY
gained [35]. Cost-effectiveness was found to be sensitive
to the reported improvement in tinnitus (QALY gain)
experienced by the patient, a variable on which there is
limited information. Further clinical research quantifying
the QALY improvements experienced by tinnitus pa-
tients would provide valuable additional insights to the
cost-effectiveness of tinnitus therapies. Other assump-
tions in the model that are based on clinician opinion
rather than data also limit confidence in the certainty of
the estimates reported.
In the current model a small number of patients who
successfully habituate after educational reassurance via
their GP generate the smallest costs; a majority of pa-
tients are necessarily referred to ENT/audiovestibular
medicine or audiology at their first or repeated GP con-
sultation where they pick up further costs and benefits.
Patients referred onwards by their GP were more likely
to receive further treatment and successfully habituate
to tinnitus as well as accruing greater costs. Patients re-
ferred through the audiology route were more likely to
be offered a variety of interventions and thus more likely
to successfully habituate than those not reaching
audiology.
The UK NHS healthcare cost of tinnitus per person
per year is estimated to be GB£717, which is comparable
to estimates in other studies examining the costs of un-
explained medical symptoms. Reed et al. [36] used pa-
tient data from the UK General Practice Research
Database, estimating annual healthcare cost per patient
with unexplained pain to vary between £582 and £925,
depending on the severity of pain (judged by number of
pain relief prescriptions over a three-month period). The
figure for tinnitus falls substantially below the GB£1100
healthcare cost of tinnitus in the Netherlands estimated
by Maes et al. [19] yet QALY estimates were compar-
able. However, the Netherlands operates a compulsory
health insurance system and differences in unit cost are
likely to explain some of this mismatch between esti-
mates for the two countries. The Maes et al. [35] cost of
hearing aids at US$1038 is about 10 times our estimate
for an NHS hearing aid.
Annual UK NHS healthcare cost and societal costs
were approximated here at £750 million, and £2.7 billion
respectively. It is striking that the prevalence of tinnitus
and likely cost to society are not reflected in the amount
of funding to support tinnitus research, in the UK or
elsewhere [37]. The UK healthcare and societal estimates
would seem surprisingly low compared to those reported
by Maes et al. [19]. They estimated that in the
Netherlands the annual healthcare cost of tinnitus is
€1.9 billion (2.3% of the country’s total healthcare ex-
penditure) and societal cost to be €6.8 billion per year.
Given the difference in population between the UK
(60 m) and the Netherlands (12.5 m), this would imply
an order of magnitude in the difference between the two
estimates. However, Maes et al. [19] based their estimate
on general tinnitus prevalence figures as opposed to pa-
tient numbers, i.e. assuming 10% (± 5%) of the popula-
tion take up healthcare services for tinnitus. The true
figure is likely to be much lower than even the lower es-
timate in their sensitivity analysis.
Pathways ending at ENT did not demonstrate cost-
effectiveness, primarily due to an unexpectedly high rate
of patients being discharged to self-manage, which in
the model was associated with no QALY gain. In con-
trast only 10% of audiology patients were estimated to
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be discharged to self-manage. These figures had a very
significant effect on estimates of cost-effectiveness and
although based on the best available evidence, need con-
firmation or correction through future service evaluations.
ENT is an essential element of the patient pathway for
many tinnitus patients and as with any medically unex-
plained condition there is significant expenditure associ-
ated with investigations seeking disease [38]. Appropriate
referral is therefore particularly important to cost effect-
iveness. For example, patients with tinnitus are unlikely to
benefit from repeated referrals to ENT services which have
already investigated any other likely diagnoses.
New pathways should explore ways of reducing un-
necessary healthcare costs and at the same time improve
quality of care for those with tinnitus. One model recently
published is a ‘one-stop tinnitus service’ [39] where the
tinnitus patient is assessed by both an audiologist and an
ENT surgeon within the same appointment. In this model
the patient has a full diagnostic work-up including routine
imaging, and leaves with a management plan, which may
be organised through their local audiology services. Whilst
the authors aim to make care accessible and reduce un-
necessary follow-up appointments, they acknowledge that
the success of the model is dependent on appropriate re-
ferral. Until alternative tinnitus care models such as this
are fully evaluated, they remain controversial. The recent
American Academy of Otolaryngology (AAO) clinical
practice guidelines [40] explicitly recommend against the
routine use of imaging as appears to be used by Farr et al.
[39]. These authors argue that it is a useful form of re-
assurance to patients, promotes acceptance of their state,
and helps reduce anxiety, whereas the AAO guidelines
conclude a preponderance of harm over benefit.
Conclusions
Overall, the cost-effectiveness of current UK tinnitus
therapies of £10,600 per QALY gained compares favourably
with the generally accepted GB£20,000/QALY threshold.
Further clinical research quantifying the QALY improve-
ments experienced by tinnitus patients would support pre-
cise evaluations on the clinical and cost effectiveness of
alternative models of patient triage and management, alter-
native patient pathways, and novel management options.
Future studies could also test our estimate of societal costs
directly with a large UK population to quantify personal
and loss of productivity costs. This will be particularly
desirable should tinnitus pathways be redesigned or when
new interventions are introduced. Whilst healthcare costs
of two interventions may be equal, personal or loss of
productivity costs may still differ substantially. Cima et al.
[23] reported higher productivity costs, specifically days of
work lost, for those patients receiving specialised care in-
stead of usual care. Proposed predictors of healthcare and
societal costs of tinnitus (tinnitus severity and duration,
severity of depression, and age) should also be tested in a
UK population.
Additional files
Additional file 1: Probabilities. Probability values and sources
corresponding to each transition in the model. (XLSX 66 kb)
Additional file 2: Tinnitus Management Pathway Definition. Pathway
descriptions. (DOCX 15 kb)
Additional file 3: The model. Utilisation of each resource in the model.
(XLSX 81 kb)
Abbreviations
BTA: British Tinnitus Association; CBT: Cognitive behavior therapy; ENT: Ear
nose and throat; GP: General practitioner; ICER: Incremental cost per QALY
gained; MRI: Magnetic resonance imaging; MTRT: Modified tinnitus retraining
therapy; NHS: National health service; NICE: National institute for health and
clinical excellence; QALY: Quality adjusted life years; TRT: Tinnitus retraining
therapy
Acknowledgements
DJH is funded through the NIHR biomedical research centre programme,
however the views expressed are those of the authors and not necessarily
those of the NIHR, the NHS, or the Department of Health.
Economic modelling (PB, CW) was funded by the British Tinnitus Association (DS).
Availability of data and materials
The dataset and model supporting the conclusions of this article are
included within the article.
Authors’ contributions
DS conceived the study. DS, PB, CP designed the work. DM, TK, CD, DJH
acquired data, PB, CP, DJH analysed data, all authors interpreted data for the
work. DJH drafted the manuscript. All authors revised it critically for
important intellectual content, gave final approval of the version to be
published, and agree to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved.
Ethics approval and consent to participate
Not applicable. Data based project.
Consent for publication
Not applicable.
Competing interests
CP and PB had support from the British Tinnitus Association for the
submitted work. DM is a Trustee of the British Tinnitus Association; DJH and
TK are chair and member respectively of the British Society of Audiology
Tinnitus and Hyperacusis Special Interest Group.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1British Tinnitus Association, Ground Floor, Unit 5, Acorn Business Park,
Woodseats Close, Sheffield S8 0TB, UK. 2Colchester Hospital University NHS
Foundation Trust, Lexden Rd, Colchester Essex CO3 3NB, UK. 3Optimity
Advisors, 1st Floor Kemp House, 152-160 City Rd, London EC1V 2DW, UK.
4Wickenstones Ltd, Unit 26, 127 Olympic Avenue, Milton Park OX14 4SA, UK.
5Aintree University Hospital NHS Foundation Trust, Lower Lane, Liverpool L9
7AL, UK. 6Department of Psychological Sciences, University of Liverpool,
Liverpool L69 3GL, UK. 7NIHR Nottingham Biomedical Research Centre,
Otology and Hearing Group, Division of Clinical Neuroscience, University of
Nottingham, Nottingham NG1 5DU, UK.
Stockdale et al. BMC Health Services Research  (2017) 17:577 Page 8 of 9
Received: 7 April 2016 Accepted: 9 August 2017
References
1. Alster J, Shemesh Z, Ornan M, et al. Sleep disturbance associated with
chronic tinnitus. Biol Psychiatry. 1993;34:84–90.
2. McKenna L, Handscomb L, Hoare DJ, et al. A scientific cognitive-behavioral
model of tinnitus: novel conceptualizations of tinnitus distress. Front Neurol.
2014;5
3. Rossiter S, Stevens C, Walker G. Tinnitus and its effect on working memory
and attention. J Speech Lang Hear Res. 2006;49:150–60.
4. Henry JA, Loovis C, Montero M, et al. Randomized clinical trial: group counseling
based on tinnitus retraining therapy. J Rehabil Res Dev. 2007;44:21–32.
5. Martinez-Devesa P, Perera R, Theodoulou M, et al. Cognitive behavioural
therapy for tinnitus. Cochrane Database Syst Rev. 2010;9:CD005233.
6. Hoare DJ, Edmondson-Jones M, Sereda M, et al. Amplification with hearing
aids for patients with tinnitus and co-existing hearing loss. Cochrane
Database Syst Rev. 2014;1:CD010151.
7. Hobson J, Chisholm E, El Refaie A. Sound therapy (masking) in the management
of tinnitus in adults. Cochrane Database Syst Rev. 2010;12:CD006371.
8. Phillips JS, McFerran D. Tinnitus retraining therapy (TRT) for tinnitus.
Cochrane Datbase Syst Rev. 2010;12:CD006371.
9. De Ridder D, Vanneste S, Elgoyhen AB, et al. All Treatments in Tinnitus Are
Experimental, Controversial, and Futuristic: A Comment on “Experimental,
Controversial, and Futuristic Treatments for Chronic Tinnitus” by Folmer
et al (2014). J Am Acad Audiol. 2015;26:595.
10. Folmer RL, Theodoroff SM, Martin WH, et al. Experimental, controversial, and
futuristic treatments for chronic tinnitus. J Am Acad Audiol. 2014;25:106–25.
11. Jastreboff PJ, Hazell JWP, Graham RL. Neurophysiological model of tinnitus:
dependence of the minimal masking level on treatment outcome. Hear Res.
1994;80:216–32.
12. Jastreboff PJ, Hazell JWP. Tinnitus retraining therapy: implementing the
neurophysiological model. Cambridge: Cambridge University Press; 2004.
13. Aazh H, Moore BC, Glasberg BR. Simplified form of tinnitus retraining therapy in
adults: a retrospective study. BMC Ear Nose Throat Disord. 2008;8:7.
14. Department of Health. Provision of services for adults with tinnitus. A good
practice guide. London, England: Central Office of Information; 2009.
15. Gander PR, Hoare DJ, Collins L, et al. Tinnitus referral pathways within the
National Health Service in England: a survey of their perceived effectiveness
among audiology staff. BMC Health Serv Res. 2011;11:162.
16. El-Shunnar SK, Hoare DJ, Smith S, et al. Primary care for tinnitus: practice
and opinion among GPs in England. J Eval Clin Pract. 2011;17:684–92.
17. Hoare DJ, Broomhead E, Stockdale D, et al. Equity in provision of tinnitus
services in United Kingdom National Health Service audiology departments.
Eur J Pers Centered Heathcare. 2015;3:318–26.
18. Goldstein E, Ho C-X, Hanna R, et al. Cost of Care for subjective tinnitus in
relation to patient satisfaction. Otolaryngol Head Neck Surg. 2015;152:518–23.
19. Maes IHL, Cima RFF, Vlayen JW, et al. 2013 Tinnitus: a cost study. Ear Hear.
2013;34:508–14.
20. Martinez C, Wallenhorst C, McFerran D, et al. Incidence rates of clinically
significant tinnitus: 10-year trend from a cohort study in England. Ear Hear.
2015;6:e69.
21. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic
evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.
22. Andersson G, Porsaeus D, Wiklund M, et al. Treatment of tinnitus in the elderly:
a controlled trial of cognitive behavior therapy. Int J Audiol. 2005;44:671–5.
23. Cima RFF, Maes IH, Joore MA, et al. Specialised treatment based on
cognitive behaviour therapy versus usual care for tinnitus: a randomised
controlled trial. Lancet. 2012;379:1951–9.
24. Davis A, Smith PA, Booth M, et al. Diagnosing patients with age-related
hearing loss and tinnitus: Supporting GP clinical engagement through
innovation and pathway redesign in audiology services. Int J Otolaryngol.
2012. Article ID 290291.
25. Dawes P, Munro KJ, Kalluri S, et al. Acclimatization to hearing aids. Ear Hear.
2014;35:203–12.
26. Hall DA, Láinez MJA, Newman CW, et al. Treatment options for subjective
tinnitus: self reports from a sample of general practitioners and ENT
physicians within Europe and the USA. BMC Health Serv Res. 2011;11:302.
27. Hoare DJ, Gander PE, Collins L, et al. Management of tinnitus in English NHS
Audiology Departments: an evaluation of current practice. J Eval Clin Pract.
2012;183:326–34.
28. Hoare DJ, Hall DA. Clinical guidelines and practice: a commentary on the
complexity of tinnitus management. Eval Heal Prof. 2010;34:413–20.
29. Nyenhuis N, Golm D, Kröner-Herwig B. A systematic review and meta-
analysis on the efficacy of self-help interventions in tinnitus. Cogn Behav
Ther. 2013;42:159–69.
30. Park S-N, Bae S-C, Kim D-K, et al. Small-group counseling in a modified
tinnitus retraining therapy for chronic tinnitus. Clin Exp Otorhinolaryngol.
2013;6:214–8.
31. Sanchez TG, de Medeiros IRT, Levy CPD, et al. Tinnitus in normally
hearing patients: clinical aspects and repercussions. Brasil J
Otorinolaringol. 2005;71:427–31.
32. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute
utility functions for the health utilities index mark 3 system. Med Care.
2002;40:113–28.
33. Swan IRC, Guy FH, Akeroyd MA. Health-related quality of life before and
after management in adults referred to otolaryngology: a prospective
national study. Clin Otolaryngol. 2012;37:35–43.
34. Office of National Statistics. 2015. https://www.ons.gov.uk/people
populationandcommunity/healthandsocialcare/healthcaresystem/articles/
expenditureonhealthcareintheuk/2015-03-26. Accessed 14 Aug 2017.
35. Maes IHL, Cima RFF, Anteunis LJC, et al. Cost-effectiveness of specialized
treatment based on cognitive behavioral therapy versus usual care for
tinnitus. Otol Neurotol. 2014;35:787–95.
36. Reed C, Hong J, Novick D, et al. Health care costs before and after diagnosis
of depression in patients with unexplained pain: a retrospective cohort
study using the United Kingdom General Practice Research Database.
Clinicoecon Outcomes Res. 2013;5:37–47.
37. Cederroth CR, Canlon B, Langguth B. Hearing loss and tinnitus-are funders
and industry listening? Nature Biotechnol. 2013;31:972–4.
38. Burton C, McGorm K, Richardson G, et al. Healthcare costs incurred by patients
repeatedly referred to secondary medical care with medically unexplained
symptoms: A cost of illness study. J Psychosom Res. 2012;72:242–7.
39. Farr MRB, Deleito JM, Xu Y, et al. Developing a one-stop tinnitus service:
outcomes of a joined up management strategy: a retrospective
observational cohort study. J Eval Clin Pract. in press;
40. Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline: Tinnitus.
Otolaryngol Head Neck Surg. 2014;151:S1.
41. Department of Health. NHS trust reference cost schedules 2012–2013. 2015.
https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-
2013. Accessed 14 Aug 2017.
42. HAB online. 2016. www.hearing-aid-batteries.org.uk. Accessed 22 Mar 2016.
43. Personal Social Services Research Unit. Unit costs of Health and Social Care
2013. 2016.http://www.pssru.ac.uk/project-pages/unit-costs/2013/. Accessed
22 Mar 2016.
44. NHS Business Services Authority. National Drug tariff. 2016. https://www.
nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-
tariff. Accessed 14 Aug 2017.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Stockdale et al. BMC Health Services Research  (2017) 17:577 Page 9 of 9
